PLA2G4F

Across TCGA pan-cancer cohorts, PLA2G4F mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated PLA2G4F data layer compared with 23 for mass-spec protein and 8 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher PLA2G4F mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated PLA2G4F expression acts as an unfavorable survival marker, although some lineages such as LUAD and CCRCC show a favorable association.

LUAD, HNSC, and CCRCC are the cancer types where PLA2G4F mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Quartile	II,III,IV	0.722	0.304	<.001	20	view →
HNSC	OS	Tertile	IV	0.554	0.990	.009	16	view →
CCRCC	OS	Quartile	All	0.974	0.534	.013	2	view →
UCEC	OS	Median	All	1.000	0.800	.042	2	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

PLA2G4F–LUAD (OS)

Open the LUAD breakdown →